AAV Applications in Peripheral Tissues: Expanding the Reach of Gene Therapy Beyond the CNS

Adeno-associated virus, or AAV, has become one of the most important gene delivery platforms in biomedical research and gene therapy development. While AAV is widely recognized for its role in central nervous system and ocular gene therapy, its applications in peripheral tissues are equally important. Peripheral organs and tissues such as the liver, skeletal muscle, heart, lung, immune system, and peripheral nervous system are central to many inherited, metabolic, inflammatory, neuromuscular, and systemic diseases.

AAV-based delivery offers researchers a flexible tool for studying gene function, modeling disease, and developing therapeutic strategies in these peripheral systems. By selecting appropriate capsids, promoters, routes of administration, and expression cassettes, AAV vectors can be tailored to deliver genes to specific organs or cell types. This has opened new opportunities for both basic research and translational gene therapy development.

AAV as a Platform for Peripheral Gene Therapy

AAV vectors can mediate gene transfer in many dividing and non-dividing cells and can support long-term transgene expression in several peripheral tissues. Depending on the application, AAV may be administered systemically, locally, intramuscularly, intrahepatically, intravascularly, intraperitoneally, or through other tissue-directed routes. This flexibility allows researchers to match vector delivery to the biology of the target disease.

In peripheral gene therapy research, AAV can be used for:

• Gene replacement for monogenic disorders.
• Expression of secreted therapeutic proteins.
• Gene silencing using shRNA, miRNA, or other regulatory systems.
• Delivery of genome editing components or guide RNAs.
• Disease modeling through tissue-specific gene expression.
• Functional studies of metabolic, immune, neuromuscular, and sensory pathways.

Although AAV has strong potential, its performance depends heavily on capsid tropism, vector dose, target tissue accessibility, immune response, and manufacturing quality. Therefore, peripheral AAV applications require careful vector design and robust preclinical evaluation.

Liver-Directed AAV Research

The liver is one of the most important peripheral targets for AAV gene therapy. Hepatocytes are highly relevant for metabolic regulation, detoxification, lipid metabolism, coagulation factor production, and secretion of circulating proteins. For this reason, liver-directed AAV vectors are widely used in research and development programs for inherited metabolic diseases, hemophilia, lysosomal storage disorders, urea cycle disorders, and lipid metabolism disorders.

AAV liver delivery is especially attractive when the therapeutic protein can be produced by hepatocytes and secreted into the bloodstream. This approach has been used in approved and investigational therapies for hemophilia, where AAV vectors deliver genes encoding clotting factors to liver cells. In research settings, liver-directed AAV also provides a powerful platform for studying gene function, disease mechanisms, and long-term expression of therapeutic proteins.

Key challenges include immune-mediated liver inflammation, pre-existing anti-AAV antibodies, high vector doses for systemic indications, durability of expression in pediatric patients, and the need for precise control of transgene expression.

AAV in Muscle and Neuromuscular Research

Skeletal muscle is another major peripheral target for AAV delivery. Muscle tissue is accessible, highly vascularized, and capable of producing local or secreted proteins. AAV vectors are widely used in neuromuscular disease research, including muscular dystrophies, metabolic myopathies, motor neuron-related disorders, and muscle regeneration studies.

AAV can be delivered locally by intramuscular injection or systemically to reach broader muscle groups. Certain AAV capsids, including naturally occurring and engineered variants, show strong muscle tropism. This makes AAV useful for studying muscle gene function, delivering micro-dystrophin or other therapeutic constructs, and evaluating disease-modifying approaches in animal models.

However, muscle-directed AAV applications often require careful attention to dose, immune response, vector distribution, and transgene size. For example, large genes may exceed AAV’s packaging capacity, requiring shortened constructs, dual-vector strategies, or alternative delivery approaches.

AAV in Peripheral Nervous System Research

The peripheral nervous system, or PNS, includes sensory neurons, motor neurons, autonomic neurons, dorsal root ganglia, peripheral nerves, and neuromuscular junctions. AAV vectors are valuable tools for studying pain, sensory function, neuropathy, motor neuron biology, and neuro-immune interactions.

AAV can be used to deliver reporters, calcium indicators, optogenetic or chemogenetic tools, gene-silencing constructs, or therapeutic genes to peripheral neurons. Depending on the capsid and delivery route, AAV may target dorsal root ganglia, peripheral nerve terminals, muscle-associated motor pathways, or autonomic circuits.

PNS applications also require careful safety evaluation. Some AAV capsids can transduce dorsal root ganglia efficiently, which may be useful for research but can also raise safety considerations in therapeutic development. Therefore, vector tropism, dose, biodistribution, and histopathology should be carefully assessed.

AAV and Immune-Related Applications

AAV is also being explored in immune and inflammatory disease research, although its use in immune cells is more complex than in some other tissues. Primary immune cells can be difficult to transduce efficiently with AAV, and immune responses to AAV capsids or transgene products may affect vector performance.

Despite these challenges, AAV can support immune-related research in several ways. It may be used to deliver cytokines, antibodies, immune modulators, antigen-specific tools, or tissue-localized regulatory proteins. AAV-mediated expression of therapeutic antibodies or immune-modifying proteins is being investigated in areas such as infectious disease, cancer, inflammation, and autoimmune disease research.

For immune applications, the key challenge is achieving the right level, location, and duration of expression without triggering unwanted immune activation or off-target effects.

Challenges in Peripheral AAV Applications

Although AAV has broad potential across peripheral tissues, several challenges must be addressed to support reliable research and therapeutic translation.

Important considerations include:

• Tissue targeting: Different capsids show different tropism, and performance can vary across species.
• Dose optimization: Systemic peripheral delivery may require high doses, increasing safety and manufacturing demands.
• Immune response: Pre-existing neutralizing antibodies, capsid-specific T-cell responses, and transgene immunity can affect efficacy and durability.
• Payload limitation: AAV’s packaging capacity of approximately 4.7 kb restricts the size of the expression cassette.
• Durability: Episomal AAV genomes may be diluted in rapidly dividing cells or growing tissues.
• Manufacturing quality: High-purity, well-characterized AAV vectors are essential for reproducible results and translational studies.
• Biodistribution: Peripheral delivery can lead to vector exposure in multiple organs, requiring careful assessment of on-target and off-target expression.

The future of AAV in peripheral research will be shaped by improved capsids, more specific promoters, optimized expression cassettes, better manufacturing platforms, and more predictive preclinical models. Engineered capsids may improve delivery to liver, muscle, heart, lung, peripheral neurons, or other tissues while reducing off-target transduction. Tissue-specific promoters and regulatory elements may further improve expression precision and safety.

As the field advances, AAV is likely to play an expanding role in peripheral gene therapy, disease modeling, biologic delivery, and functional genomics. The most successful applications will be those that carefully align vector design with disease biology, target tissue, route of administration, and clinical feasibility.

Conclusion

AAV applications in peripheral research are expanding the possibilities of gene delivery beyond the central nervous system. From liver-directed therapies and muscle disease models to peripheral nerve studies and immune-related applications, AAV provides a versatile platform for exploring disease mechanisms and developing innovative therapeutic strategies.

While challenges remain, continued advances in AAV capsid engineering, tissue-specific expression, delivery methods, and analytical characterization are making peripheral AAV applications more precise, reproducible, and translationally relevant.